Spectral Shift for Ultra-High-Throughput Binding Assays

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection mass spectrometry (ASMS) can be limited by sensitivity or sample demand.  Spectral Shift is a fluorescence-based biophysical technique used to quantify the strength of molecular interactions. It offers a powerful alternative to traditional biochemical assays and ASMS, directly quantifying protein–ligand interactions in a high-throughput format.

At DDC 2026, WuXi AppTec presented a poster showcasing this underlying technology, detailing our in-house implementations and optimized screening workflows, and highlighting a successful case study targeting PIK3CA H1047R. The results demonstrate the assay’s robust performance and broad applicability in accelerating early-stage drug discovery.

Poster_DDC 2026_Unleashing the Power of Spectral Shift Technology for Ultra-High-Throughput Binding Assays

Download